Business Description
Maat Pharma SA
ISIN : FR0012634822
Compare
Compare
Traded in other countries / regions
MAAT.France4RD.Germany IPO Date
2021-11-11Description
Maat Pharma SA is a french clinical stage biotech and a pioneer in the development of microbiome based ecosystem therapies dedicated to improving survival outcomes for patients with cancer.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.87 | |||||
| Equity-to-Asset | 0.5 | |||||
| Debt-to-Equity | 0.67 | |||||
| Debt-to-EBITDA | -0.78 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 1.51 | |||||
| Beneish M-Score | -1.89 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 31 | |||||
| 3-Year EPS without NRI Growth Rate | 30.6 | |||||
| 3-Year FCF Growth Rate | 33.7 | |||||
| 3-Year Book Growth Rate | -51.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 30.92 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 106.39 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 40.67 | |||||
| 9-Day RSI | 45.83 | |||||
| 14-Day RSI | 48.27 | |||||
| 6-1 Month Momentum % | 6.7 | |||||
| 12-1 Month Momentum % | 14.37 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.76 | |||||
| Quick Ratio | 2.75 | |||||
| Cash Ratio | 2.18 | |||||
| Days Inventory | 65.32 | |||||
| Days Sales Outstanding | 128.67 | |||||
| Days Payable | 2296.95 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -124 | |||||
| Shareholder Yield % | -18.67 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 67.83 | |||||
| Operating Margin % | -939.95 | |||||
| Net Margin % | -938.86 | |||||
| FCF Margin % | -734.81 | |||||
| ROE % | -93.6 | |||||
| ROA % | -50.42 | |||||
| ROIC % | -157.98 | |||||
| 3-Year ROIIC % | -117.35 | |||||
| ROC (Joel Greenblatt) % | -288.7 | |||||
| ROCE % | -66.83 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 37.01 | |||||
| PB Ratio | 4.3 | |||||
| Price-to-Tangible-Book | 4.14 | |||||
| EV-to-EBIT | -4.13 | |||||
| EV-to-EBITDA | -4.42 | |||||
| EV-to-Revenue | 38.03 | |||||
| EV-to-FCF | -5.06 | |||||
| Price-to-Net-Current-Asset-Value | 6.57 | |||||
| Price-to-Net-Cash | 14.65 | |||||
| Earnings Yield (Greenblatt) % | -24.18 | |||||
| FCF Yield % | -16.75 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Maat Pharma SA Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 2.571 | ||
| EPS (TTM) (€) | -1.99 | ||
| Beta | 0.36 | ||
| Volatility % | 31.05 | ||
| 14-Day RSI | 48.27 | ||
| 14-Day ATR (€) | 0.340333 | ||
| 20-Day SMA (€) | 7.781 | ||
| 12-1 Month Momentum % | 14.37 | ||
| 52-Week Range (€) | 5.82 - 9.92 | ||
| Shares Outstanding (Mil) | 13.95 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Maat Pharma SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Maat Pharma SA Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Maat Pharma SA Frequently Asked Questions
What is Maat Pharma SA(FRA:4RD)'s stock price today?
The current price of FRA:4RD is €7.62. The 52 week high of FRA:4RD is €9.92 and 52 week low is €5.82.
When is next earnings date of Maat Pharma SA(FRA:4RD)?
The next earnings date of Maat Pharma SA(FRA:4RD) is 2025-03-28 Est..
Does Maat Pharma SA(FRA:4RD) pay dividends? If so, how much?
Maat Pharma SA(FRA:4RD) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers